Phase II of Lenvatinib Plus Programmed Cell Death 1 Antibody for Advanced Hepatocellular Carcinoma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2019
Price : $35 *
At a glance
- Drugs Lenvatinib (Primary) ; Lenvatinib (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Therapeutic Use
- 15 Apr 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.
- 12 Dec 2018 Planned number of patients changed from 80 to 25.